COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,802 Articles (22,527 medRxiv, 8,275 bioRxiv)

Most recent first Previous |  Page 854: Articles 8531-8540  | Next

Ammonium Sulfate Addition Reduces the Need for Guanidinium Isothiocyanate in the Denaturing Transport Medium Used for SARS-COV-2 RNA Detection
Liu, G., Jia, J., Zhong, J., Jiang, H., Yang, Y., Lu, X., He, Z., Zhu, Q.
10.1101/2022.02.28.22271591 — Posted: 2022-03-02
Patients with CLL have similar high risk of death upon the omicron variant of COVID-19 as previously during the pandemic.
Niemann, C. U., da Cunha-Bang, C., Helleberg, M., Ostrowski, S. R., Brieghel, C.
10.1101/2022.03.01.22271685 — Posted: 2022-03-02
Assessment of Potential Risk Factors for COVID-19 among Health Care Workers in a Health Care Setting in Delhi, India -A Cohort Study
Dudeja, M., Shaikh, A., Islam, F., Alvi, Y., Ahmad, M., Kashyap, V., Singh, V., Rahman, A., Panda, M., Shree, N., Nandy, S., Jain, V.
10.1101/2022.02.28.22271674 — Posted: 2022-03-02
A causal inference approach for estimating effects of non-pharmaceutical interventions during Covid-19 pandemic
Barros, V., Manes, I., Akinwande, V., Cintas, C., Bar-Shira, O., Ozery-Flato, M., Shimoni, Y., Rosen-Zvi, M.
10.1101/2022.02.28.22271671 — Posted: 2022-03-02
Unquantifiably low aldosterone concentrations are prevalent in hospitalised COVID-19 patients but may not be revealed by chemiluminescent immunoassay
Wiegand, M., Halsall, D. J., Cowan, S. L., Taylor, K., Goudie, R. J., Preller, J., Gurnell, M.
10.1101/2022.02.28.22271645 — Posted: 2022-03-01
Rapid review of government issued documents relevant to mitigation of COVID-19 in the US food manufacturing and processing industry
Chen, Z., Bulut, E., Trmcic, A., Ivanek, R.
10.1101/2022.02.25.22271516 — Posted: 2022-03-01
Fine-scale variation in the effect of national border on COVID-19 spread: A case study of the Saxon-Czech border region
Mertel, A., Vyskocil, J., Schüler, L., Schlechte-Wełnicz, W., Calabrese, J. M.
10.1101/2022.03.01.22271644 — Posted: 2022-03-01
Stable nebulization and muco-trapping properties of Regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19
McSweeney, M. D., Stewart, I., Richardson, Z., Kang, H., Park, Y., Kim, C., Tiruthani, K., Wolf, W., Schaefer, A., Kumar, P., Aurora, H., Hutchins, J., Cho, J. M., Hickey, A. J., Lee, S. Y., Lai, S. K.
10.1101/2022.02.27.482162 — Posted: 2022-03-01
Myocarditis and Pericarditis following COVID-19 Vaccination: Evidence Syntheses on Incidence, Risk Factors, Natural History, and Hypothesized Mechanisms
Pillay, J., Gaudet, L., Wingert, A., Bialy, L., Mackie, A. S., Paterson, I., Hartling, L.
10.1101/2022.02.28.22271643 — Posted: 2022-03-01
Cross-cultural adaptation and validation of the COVID Stress Scales in Greek
Galanis, P. A., Vraka, I., Katsiroumpa, A., Konstantakopoulou, O., Siskou, O., Zogaki, E., Kaitelidou, D.
10.1101/2022.02.28.22271615 — Posted: 2022-03-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).